Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study.
Aged
Alzheimer Disease
/ cerebrospinal fluid
Amyloid beta-Peptides
/ cerebrospinal fluid
Biomarkers
/ cerebrospinal fluid
Cognitive Dysfunction
/ cerebrospinal fluid
Diagnostic Self Evaluation
Female
Humans
Longitudinal Studies
Male
Mental Status and Dementia Tests
Middle Aged
Peptide Fragments
/ cerebrospinal fluid
Prodromal Symptoms
Aß42
CSF biomarkers
Cerebrospinal fluid (CSF)
Preclinical AD
Preclinical Alzheimer’s disease (AD)
Subjective cognitive decline (SCD)
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
31 07 2019
31 07 2019
Historique:
received:
15
03
2019
accepted:
02
07
2019
entrez:
2
8
2019
pubmed:
2
8
2019
medline:
17
7
2020
Statut:
epublish
Résumé
Subjective cognitive decline (SCD) has been proposed as a pre-MCI at-risk condition of Alzheimer's disease (AD). Current research is focusing on a refined assessment of specific SCD features associated with increased risk for AD, as proposed in the SCD-plus criteria. We developed a structured interview (SCD-I) for the assessment of these features and tested their relationship with AD biomarkers. We analyzed data of 205 cognitively normal participants of the DELCODE study (mean age = 68.9 years; 52% female) with available CSF AD biomarkers (Aß-42, p-Tau181, Aß-42/Tau ratio, total Tau). For each of five cognitive domains (including memory, language, attention, planning, others), a study physician asked participants about the following SCD-plus features: the presence of subjective decline, associated worries, onset of SCD, feeling of worse performance than others of the same age group, and informant confirmation. We compared AD biomarkers of subjects endorsing each of these questions with those who did not, controlling for age. SCD was also quantified by two summary scores: the number of fulfilled SCD-plus features, and the number of domains with experienced decline. Covariate-adjusted linear regression analyses were used to test whether these SCD scores predicted abnormality in AD biomarkers. Lower Aß-42 levels were associated with a reported decline in memory and language abilities, and with the following SCD-plus features: onset of subjective decline within 5 years, confirmation of cognitive decline by an informant, and decline-related worries. Furthermore, both quantitative SCD scores were associated with lower Aß42 and lower Aß42/Tau ratio, but not with total Tau or p-Tau181. Findings support the usefulness of a criterion-based interview approach to assess and quantify SCD in the context of AD and validate the current SCD-plus features as predictors of AD pathology. While some features seem to be more closely associated with AD biomarkers than others, aggregated scores over several SCD-plus features or SCD domains may be the best predictors of AD pathology.
Sections du résumé
BACKGROUND
Subjective cognitive decline (SCD) has been proposed as a pre-MCI at-risk condition of Alzheimer's disease (AD). Current research is focusing on a refined assessment of specific SCD features associated with increased risk for AD, as proposed in the SCD-plus criteria. We developed a structured interview (SCD-I) for the assessment of these features and tested their relationship with AD biomarkers.
METHODS
We analyzed data of 205 cognitively normal participants of the DELCODE study (mean age = 68.9 years; 52% female) with available CSF AD biomarkers (Aß-42, p-Tau181, Aß-42/Tau ratio, total Tau). For each of five cognitive domains (including memory, language, attention, planning, others), a study physician asked participants about the following SCD-plus features: the presence of subjective decline, associated worries, onset of SCD, feeling of worse performance than others of the same age group, and informant confirmation. We compared AD biomarkers of subjects endorsing each of these questions with those who did not, controlling for age. SCD was also quantified by two summary scores: the number of fulfilled SCD-plus features, and the number of domains with experienced decline. Covariate-adjusted linear regression analyses were used to test whether these SCD scores predicted abnormality in AD biomarkers.
RESULTS
Lower Aß-42 levels were associated with a reported decline in memory and language abilities, and with the following SCD-plus features: onset of subjective decline within 5 years, confirmation of cognitive decline by an informant, and decline-related worries. Furthermore, both quantitative SCD scores were associated with lower Aß42 and lower Aß42/Tau ratio, but not with total Tau or p-Tau181.
CONCLUSIONS
Findings support the usefulness of a criterion-based interview approach to assess and quantify SCD in the context of AD and validate the current SCD-plus features as predictors of AD pathology. While some features seem to be more closely associated with AD biomarkers than others, aggregated scores over several SCD-plus features or SCD domains may be the best predictors of AD pathology.
Identifiants
pubmed: 31366409
doi: 10.1186/s13195-019-0515-y
pii: 10.1186/s13195-019-0515-y
pmc: PMC6668160
doi:
Substances chimiques
Amyloid beta-Peptides
0
Biomarkers
0
Peptide Fragments
0
amyloid beta-protein (1-42)
0
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
66Références
EMBO Mol Med. 2017 Sep;9(9):1212-1223
pubmed: 28743782
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Gerontologist. 2019 Mar 14;59(2):290-302
pubmed: 29325011
Neurology. 2015 Jul 7;85(1):56-62
pubmed: 26048028
Compr Psychiatry. 1994 Jul-Aug;35(4):316-27
pubmed: 7956189
J Alzheimers Dis. 2015 Sep 24;48 Suppl 1:S87-98
pubmed: 26445275
Alzheimers Dement (N Y). 2018 Sep 06;4:444-449
pubmed: 30258973
Int J Alzheimers Dis. 2012;2012:725329
pubmed: 22536537
Alzheimers Dement. 2014 Nov;10(6):844-52
pubmed: 24798886
Neuropsychologia. 2012 Oct;50(12):2880-6
pubmed: 22940426
Brain Imaging Behav. 2018 Feb;12(1):78-86
pubmed: 28108945
Alzheimers Dement. 2017 May;13(5):550-560
pubmed: 27693187
Alzheimers Dement (Amst). 2018 Mar 24;10:322-331
pubmed: 29780876
Alzheimers Res Ther. 2018 Aug 7;10(1):76
pubmed: 30081935
Arch Neurol. 2012 Feb;69(2):223-9
pubmed: 22332189
Alzheimers Dement (Amst). 2016 Dec 18;5:23-34
pubmed: 28054025
Curr Opin Psychiatry. 2012 Nov;25(6):445-50
pubmed: 23037961
J Alzheimers Dis. 2014;41(2):453-66
pubmed: 24625794
Alzheimers Dement (Amst). 2015 May 02;1(2):194-205
pubmed: 27239504
Neurology. 2018 Jul 24;91(4):e300-e312
pubmed: 29959257
Alzheimers Res Ther. 2018 Dec 20;10(1):123
pubmed: 30572953
Neurology. 2018 Apr 24;90(17):e1452-e1460
pubmed: 29572282
BMC Psychol. 2018 May 21;6(1):23
pubmed: 29784047
J Alzheimers Dis. 2015 Sep 24;48 Suppl 1:S63-86
pubmed: 26402085
Neurology. 2015 Mar 24;84(12):1261-8
pubmed: 25716354
J Affect Disord. 2002 Nov;72(2):157-65
pubmed: 12200206
Neurology. 2015 Nov 24;85(21):1852-8
pubmed: 26511452
Alzheimers Dement. 2015 Nov;11(11):1385-92
pubmed: 25667997
Neurology. 2012 Feb 7;78(6):379-86
pubmed: 22238414
Cold Spring Harb Perspect Med. 2012 Apr;2(4):a006171
pubmed: 22474609
Dement Geriatr Cogn Disord. 2007;24(2):118-24
pubmed: 17622715
Alzheimers Dement. 2017 Mar;13(3):296-311
pubmed: 27825022
Front Aging Neurosci. 2017 Nov 21;9:377
pubmed: 29201004
Neurology. 1999 May 12;52(8):1555-62
pubmed: 10331678
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
J Clin Epidemiol. 2014 Aug;67(8):845-9
pubmed: 24766858
Front Aging Neurosci. 2019 Jan 25;11:7
pubmed: 30760996
J Alzheimers Dis. 2016 Oct 4;54(3):1135-1146
pubmed: 27567852
JAMA Neurol. 2017 Dec 1;74(12):1455-1463
pubmed: 28973551
Alzheimers Res Ther. 2018 Feb 07;10(1):15
pubmed: 29415768
Alzheimers Dement. 2011 May;7(3):280-92
pubmed: 21514248
Neuropsychology. 2015 Jul;29(4):571-81
pubmed: 25664464
JAMA. 2015 May 19;313(19):1924-38
pubmed: 25988462
Eur Arch Psychiatry Clin Neurosci. 2014 Nov;264 Suppl 1:S3-7
pubmed: 25238934